National Institutes of Health Selects Humanigen’
Post# of 148169
(Total Views: 872)
Posted On: 07/27/2020 5:17:08 PM
National Institutes of Health Selects Humanigen’s Lenzilumab for its COVID-19 Big Effect Trial
Lenzilumab will be evaluated in combination with remdesivir and compared to placebo and remdesivir
The trial is expected to enroll 100 patients in each arm of the study with an interim analysis for efficacy after 50 patients have been enrolled in each arm.
Source Link: https://www.businesswire.com/news/home/202007...b-COVID-19
Lenzilumab will be evaluated in combination with remdesivir and compared to placebo and remdesivir
The trial is expected to enroll 100 patients in each arm of the study with an interim analysis for efficacy after 50 patients have been enrolled in each arm.
Source Link: https://www.businesswire.com/news/home/202007...b-COVID-19
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼